The use of rapid respiratory pathogen (RRP) testing among children with influenza-like illness (ILI) did not reduce antibiotic prescribing, according to a randomized clinical trial published late last week in JAMA Network Open.
Watching a brief video about antibiotic treatment prior to a family practitioner visit reduced patients' expectations about receiving antibiotics for upper respiratory tract infections (URTIs) but had no influence on physician prescribing, according to a randomized controlled trial published this week in the Annals of Family Medicine.
Less than 0.1% of all COVID-positive patients in the Intermountain Healthcare system had probable or possible recurrence of SARS-CoV-2 infection, according to a PLOS One study yesterday.
The Democratic Republic of the Congo (DRC) health ministry today declared the end of the country's 12th Ebola outbreak, given that 42 days have passed with no new cases since the last patient was released from treatment.
CARB-X announced today that it is awarding up to $3.6 million in funding to Novel Microdevices, Inc. of Baltimore to develop a rapid, portable molecular diagnostic test for sexually transmitted bacterial infections.
Eight people have been hospitalized amid a 19-person Salmonella outbreak linked to wild songbirds in eight states, according to a Centers for Disease Control and Prevention (CDC) investigation notice released yesterday.
The first global assessment of the collateral impact of the COVID-19 pandemic on pregnancy outcomes found a significant increase in stillbirths, maternal deaths, maternal depression, and women requiring surgery for ectopic pregnancy, researchers reported yesterday in The Lancet Global Health.
Since the introduction of the human papillomavirus (HPV) vaccine in 2006, rates of HPV infections among females fell 88% in teens 14 to 19 years and by 81% in those aged 20 to 24 by 2018, according to a study today in Morbidity and Mortality Weekly Report (MMWR).
People with COVID-19 infections who also used the inflammatory bowel disease (IBD) drug infliximab had significantly fewer detectable antibodies than those who used vedolizumab, which treats IBD without the immune suppression, according to a study yesterday in Gut.
The National Institute of Allergy and Infectious Diseases (NIAID) announced yesterday that it has awarded $2.5 million in grants to support research on bacteriophage therapy.
